Investigating and targeting metabolic vulnerabilities of MYC-driven small cell lung cancer

研究和靶向 MYC 驱动的小细胞肺癌的代谢脆弱性

基本信息

  • 批准号:
    10748278
  • 负责人:
  • 金额:
    $ 4.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT ABSTRACT Small cell lung cancer (SCLC) is a fatal neuroendocrine lung tumor that is challenging to treat due to early metastasis, rapid growth, and a lack of easily targetable driver alterations. For the last ~40 years, SCLC has been treated primarily as a single disease in the clinic with combination, platinum-based chemotherapy that offers a median survival of only ~10-12 months. It is imperative to better understand SCLC biology to enable development of novel treatment strategies that effectively prolong patient survival. SCLC tumors amplify or overexpress one oncogenic MYC family member: MYC, MYCL, or MYCN. MYC-high SCLCs are metabolically distinct from MYC-low, and have specific and targetable metabolic vulnerabilities. The most effective therapeutic strategy for treatment of MYC-high SCLCs in preclinical trials is deprivation of circulating arginine by pegylated arginine deiminase (ADI-PEG20). MYC-high SCLCs are particularly sensitive to ADI-PEG20, because they lack the enzyme argininosuccinate synthetase 1 (ASS1) that catalyzes de novo synthesis of arginine by the urea cycle. Still, SCLC tumors eventually develop resistance to ADI-PEG20 (ADIR) that corresponds with re- expression of ASS1. Upon ADIR, tumors acquire secondary metabolic dependencies that may be targeted to prolong ADI-PEG20 response and patient survival. Preliminary data show that ADIR SCLC depends on serine and one-carbon (1C) metabolism, which can be targeted with anti-folates. Preliminary data also delineate candidate transcriptional regulators that may govern ADIR in SCLC. Activating transcription factor 4 (ATF4), a stress-responsive transcription factor, is one predicted upstream regulator of gene programs enriched in ADIR vs naïve SCLCs—determined by bulk and single-cell RNA sequencing. ATF4 is induced upon acute arginine deprivation in SCLC and continues to be expressed with its target genes during ADIR. Here, the applicant will employ a single-cell RNA-seq-derived model of SCLC response to ADI-PEG20, metabolite profiling, in vivo isotope tracing, and CRISPR-based gene editing to interrogate whether ATF4 governs ADIR. The hypothesis for this research is that ATF4 drives ADIR by enhancing serine and 1C metabolism in an ASS1-dependent manner. Experiments will be performed in two specific aims to test whether ATF4 governs: 1) the sensitivity of MYC-high SCLCs to ADI-PEG20, and/or 2) the sensitivity of ADIR SCLCs to 1C metabolism inhibitors. Knowledge gleaned from this research will inform combination treatment strategies that improve the efficacy of ADI-PEG20 and extend survival of patients with SCLC and other ASS1-low tumors. The proposed research will provide unique opportunities for the applicant to gain expertise in cancer biology, cancer metabolism, and computational analysis of -omics data—three major goals of the applicant’s training plan. The proposed research will occur over three years of training at Huntsman Cancer Institute and the University of Utah, a collaborative and resource-rich training environment, in the lab of Dr. Trudy Oliver.
项目摘要 小细胞肺癌(SCLC)是一种致命的神经内分泌肺肿瘤,由于以下原因治疗起来具有挑战性 早期转移、快速生长以及缺乏易于靶向的驱动改变。在过去约 40 年里,SCLC 在临床上主要将其作为单一疾病进行治疗,采用基于铂类的联合化疗, 中位生存期仅为约 10-12 个月。必须更好地了解 SCLC 生物学,以实现 开发新的治疗策略,有效延长患者的生存期。 SCLC 肿瘤扩增或 过度表达一种致癌 MYC 家族成员:MYC、MYCL 或 MYCN。 MYC 高的 SCLC 具有代谢性 与 MYC-low 不同,并且具有特定的、可针对的代谢脆弱性。最有效的治疗方法 临床前试验中治疗高 MYC SCLC 的策略是通过聚乙二醇化剥夺循环精氨酸 精氨酸脱亚胺酶(ADI-PEG20)。 MYC 高的 SCLC 对 ADI-PEG20 特别敏感,因为它们缺乏 精氨酸琥珀酸合成酶 1 (ASS1),催化尿素从头合成精氨酸 循环。尽管如此,SCLC 肿瘤最终会对 ADI-PEG20 (ADIR) 产生耐药性,这与重新 ASS1 的表达。 ADIR 后,肿瘤获得次级代谢依赖性,可能针对 延长 ADI-PEG20 反应和患者生存期。初步数据表明 ADIR SCLC 依赖于丝氨酸 和一碳(1C)代谢,可以用抗叶酸药物来靶向。初步数据也描绘了 可能控制 SCLC 中 ADIR 的候选转录调节因子。激活转录因子 4 (ATF4) 应激反应转录因子,是一种预测的富含 ADIR 的基因程序上游调节因子 与初始 SCLC——通过批量和单细胞 RNA 测序确定。 ATF4 由急性精氨酸诱导 SCLC 中的剥夺并在 ADIR 期间继续与其靶基因一起表达。在此,申请人将 采用单细胞 RNA-seq 衍生的 SCLC 对 ADI-PEG20 反应的模型,体内代谢物分析 同位素追踪和基于 CRISPR 的基因编辑来询问 ATF4 是否控制 ADIR。假设为 这项研究表明,ATF4 通过以 ASS1 依赖性方式增强丝氨酸和 1C 代谢来驱动 ADIR。 实验将针对两个特定目标进行,以测试 ATF4 是否具有控制作用:1)MYC-high 的敏感性 SCLC 对 ADI-PEG20 的敏感性,和/或 2) ADIR SCLC 对 1C 代谢抑制剂的敏感性。收集到的知识 这项研究将为联合治疗策略提供信息,以提高 ADI-PEG20 的疗效和 延长 SCLC 和其他 ASS1 低肿瘤患者的生存期。拟议的研究将提供独特的 申请人有机会获得癌症生物学、癌症代谢和计算方面的专业知识 组学数据分析——申请人培训计划的三个主要目标。拟议的研究将发生 在亨茨曼癌症研究所和犹他大学接受了三年多的培训,这是一个合作和 资源丰富的培训环境,在Trudy Oliver博士的实验室。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ABBIE SHAYE IRELAND其他文献

ABBIE SHAYE IRELAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ABBIE SHAYE IRELAND', 18)}}的其他基金

Investigating and targeting metabolic vulnerabilities of MYC-driven small cell lung cancer
研究和针对 MYC 驱动的小细胞肺癌的代谢脆弱性
  • 批准号:
    10535989
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了